Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE:NVOreported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER).

  • Diabetes and Obesity care sales drove the increased sales as GLP-1 sales increased by 36% at CER. Obesity care sales increased by 73%, partially offset by decreased insulin sales by 1%. Biopharm sales increased by 6% at CER.
  • Novo reported a fourth-quarter operating profit of DKK 13.63 billion, an increase of 16% at CER over the corresponding period last year.
  • Related: FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report.
  • In December, a contract manufacturer halted deliveries and manufacturing temporarily after issues relating to good manufacturing practice.
  • Fewer new weekly patient initiations are expected in 1H of 2022 compared to Q4 FY21. Novo Nordisk still hopes to meet demand in the U.S. in 2H of 2022.
  • Share Buyback: The Board of Directors intends to initiate a new 12-month share repurchase program of up to DKK 22 billion.
  • Guidance: The company expects to generate sales growth of 6% - 10% and deliver operating profit growth of 4% - 8% at CER in 2022.
  • Price Action: NVO shares are up 3.89% at $106.60 on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.